Format

Send to

Choose Destination
Curr Atheroscler Rep. 2015 Apr;17(4):499. doi: 10.1007/s11883-015-0499-4.

Targeting PCSK9 for therapeutic gains.

Author information

1
The Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, USA.

Abstract

Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.

PMID:
25712137
PMCID:
PMC5560054
DOI:
10.1007/s11883-015-0499-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center